Evidence for the Efficacy and Effectiveness of THC-CBD Oromucosal Spray for Patients with Multiple Sclerosis
Evidence for the Efficacy and Effectiveness of THC-CBD Oromucosal Spray in Symptom Management of Patients with Spasticity Due to Multiple Sclerosis
Therapeutic Advances in Neurological Disorders:
For a summary of the available data on this cannabinoid oromucosal spray for MS-related spasticity, see the review article at the link below. This review article reports the results of studies involving thousands of patients with MS-related spasticity that provide evidence of the efficacy and safety of this cannabis-derived spray in moderate to severe spasticity associated with multiple sclerosis that cannot be fully relieved with available therapies. Of note, initial responders can be identified in a 4-week trial period, and this therapy must be titrated to the right dose for the patient.
Ther Adv Neurol Disord. 2016 Jan; 9(1): 9–30. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Uwe K. Zettl, Paulus Rommer, Petra Hipp, and Robert Patejdl